Effort-related effects of chronic administration of the DA D
Avolition
Dopamine
Motivation
Negative
Schizophrenia
Symptoms
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
06
04
2023
accepted:
27
07
2023
medline:
19
9
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Long-acting antipsychotics such as haloperidol decanoate are becoming more commonly used. Long-acting depot formulations have several advantages, but secondary negative effects of prolonged delivery, including motivational dysfunctions, could have debilitating effects. Assessing the behavioral changes that emerge during chronic antipsychotic administration in rats could provide insight regarding the development of motivational dysfunctions and drug tolerance. Acute administration of dopamine D2 antagonists such as haloperidol induce motivational deficits in rats, as marked by a shift towards a low-effort bias during effort-based choice tasks. In the present studies, programmable subcutaneous infusion pumps provided continuous and controlled drug delivery of haloperidol. Animals were assessed using a fixed ratio (FR) 5 lever pressing schedule and the FR5/chow feeding test of effort-based choice. The adenosine A Continuous chronic infusions of haloperidol produced significant reductions in FR5 performance and a shift from lever pressing to chow intake in rats tested on FR5/chow feeding choice, with no evidence of tolerance over the 4-week infusion period. Behavior returned to baseline during the vehicle-infusion washout period. Istradefylline significantly reversed the effects of haloperidol, increasing lever pressing and decreasing chow intake in haloperidol-treated rats. These studies provide an important behavioral characterization of the effects of chronically infused haloperidol, and demonstrate that A
Identifiants
pubmed: 37615683
doi: 10.1007/s00213-023-06439-y
pii: 10.1007/s00213-023-06439-y
doi:
Substances chimiques
Haloperidol
J6292F8L3D
istradefylline
2GZ0LIK7T4
Antipsychotic Agents
0
Purines
0
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2173-2185Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abe C, Tashiro T, Tanaka K, Ogihara R, Morita H (2009) A novel type of implantable and programmable infusion pump for small laboratory animals. J Pharmacol Toxicol Methods 59(1):7–12. https://doi.org/10.1016/j.vascn.2008.09.002
doi: 10.1016/j.vascn.2008.09.002
pubmed: 18852057
Abe K, Fujita M, Yoshikawa H (2016) Effectiveness of Istradefylline for Fatigue and Quality of Life in Parkinson’s Disease Patients’ and of Their Caregivers’. Adv Parkinson’s Dis 5:24–28
doi: 10.4236/apd.2016.52004
Aberman JE, Salamone JD (1999) Nucleus accumbens dopamine depletions make rats more sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience 92(2):545–552. https://doi.org/10.1016/s0306-4522(99)00004-4
doi: 10.1016/s0306-4522(99)00004-4
pubmed: 10408603
Artaloytia JF, Arango C, Lahti A et al (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163(3):488–493. https://doi.org/10.1176/appi.ajp.163.3.488
doi: 10.1176/appi.ajp.163.3.488
pubmed: 16513871
Bailey MR, Chun E, Schipani E, Balsam PD, Simpson EH (2020) Dissociating the effects of dopamine D2 receptors on effort-based versus value-based decision making using a novel behavioral approach. Behav Neurosci 134(2):101–118. https://doi.org/10.1037/bne0000361
doi: 10.1037/bne0000361
pubmed: 32175760
pmcid: 7802819
Barch DM, Gold JM, Kring AM (2017) Paradigms for assessing hedonic processing and motivation in humans: relevance to understanding negative symptoms in psychopathology. Schizophr Bull 43(4):701–705
doi: 10.1093/schbul/sbx063
pubmed: 28969354
pmcid: 5472132
Barnes SA, Der-Avakian A, Markou A (2014) Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24(5):744–758. https://doi.org/10.1016/j.euroneuro.2013.10.001
doi: 10.1016/j.euroneuro.2013.10.001
pubmed: 24183826
Bitter I, Fehér L, Tényi T, Czobor P (2015) Treatment adherence and insight in schizophrenia. Psychiatr Hung 30(1):18–26
pubmed: 25867885
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4(5):198–219. https://doi.org/10.1177/2045125314540297
doi: 10.1177/2045125314540297
pubmed: 25360245
pmcid: 4212490
Caligiuri MP, Ellwanger J (2000) Motor and cognitive aspects of motor retardation in depression. J Affect Disord 57:83–93
doi: 10.1016/S0165-0327(99)00068-3
pubmed: 10708819
Canonica T, Zalachoras I (2022) Motivational disturbances in rodent models of neuropsychiatric disorders. Front Behav Neurosci 16:940672. https://doi.org/10.3389/fnbeh.2022.940672
doi: 10.3389/fnbeh.2022.940672
pubmed: 36051635
pmcid: 9426724
Chouinard G, Jones B, Remington G et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [published correction appears in J Clin Psychopharmacol 1993 Apr; 13(2):149]. J Clin Psychopharmacol 3(1):25–40
Cousins MS, Salamone JD (1994) Nucleus accumbens dopamine depletions in rats affect relative response allocation in a novel cost/benefit procedure. Pharmacol Biochem Behav 49(1):85–91. https://doi.org/10.1016/0091-3057(94)90460-x
doi: 10.1016/0091-3057(94)90460-x
pubmed: 7816895
Culbreth AJ, Moran EK, Kandala S, Westbrook A, Barch DM (2020) Effort, avolition and motivational experience in schizophrenia: Analysis of behavioral and neuroimaging data with relationships to daily motivational experience. Clin Psychol Sci 8(3):555–568. https://doi.org/10.1177/2167702620901558
doi: 10.1177/2167702620901558
pubmed: 33758684
pmcid: 7983405
Demyttenaere K, De Fruyt J, Stahl SM (2005) The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 8:93–105. https://doi.org/10.1017/S1461145704004729
doi: 10.1017/S1461145704004729
pubmed: 15482632
Eklund K, Forsman A (1991) Minimal effective dose and relapse - double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol 14(2):7–15 (CSzG: Ref 747)
Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008) Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 30(12):2378–2386. https://doi.org/10.1016/j.clinthera.2008.12.020
doi: 10.1016/j.clinthera.2008.12.020
pubmed: 19167596
Errante EL, Chakkalamuri M, Akinbo OI, Yohn SE, Salamone JD, Matuszewich L (2021) Sex differences in effort-related decision-making: role of dopamine D2 receptor antagonism. Psychopharmacology 238(6):1609–1619. https://doi.org/10.1007/s00213-021-05795-x
doi: 10.1007/s00213-021-05795-x
pubmed: 33590311
Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen MR, Marwa ME, AlMounayer N (2019) Haloperidol discontinuation for people with schizophrenia. Cochrane Database Syst Rev 4(4):CD011408. https://doi.org/10.1002/14651858.CD011408.pub2
Farrar AM, Segovia KN, Randall PA, Nunes EJ, Collins LE, Stopper CM, Port RG, Hockemeyer J, Müller CE, Correa M, Salamone JD (2010) Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. Neuroscience 166:1056–1067
doi: 10.1016/j.neuroscience.2009.12.056
pubmed: 20096336
Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P et al (2014) Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety 31:250–257
doi: 10.1002/da.22199
pubmed: 24115209
Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G (2015) Measuring motivation in people with schizophrenia. Schizophr Res 169(1–3):423–426. https://doi.org/10.1016/j.schres.2015.09.012
doi: 10.1016/j.schres.2015.09.012
pubmed: 26391283
Friedman JH, Brown RG, Comella C, Garber CE et al (2007) Fatigue in Parkinson’s Disease: A review. Mov Disord 22:297–308
doi: 10.1002/mds.21240
pubmed: 17133511
Gao J, Li M (2013) Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav Brain Res 257:286–294. https://doi.org/10.1016/j.bbr.2013.09.050
doi: 10.1016/j.bbr.2013.09.050
pubmed: 24103641
Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ (2013) Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry 74(2):130–136. https://doi.org/10.1016/j.biopsych.2012.12.022
doi: 10.1016/j.biopsych.2012.12.022
pubmed: 23394903
pmcid: 3703817
Harvey RC, James AC, Shields GE (2016) A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs 30(1):27–39. https://doi.org/10.1007/s40263-015-0308-1
doi: 10.1007/s40263-015-0308-1
pubmed: 26801655
Kelley ME, van Kammen DP, Allen DN (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiat 156 (3), 406–411. https://doi-org.ezproxy.lib.uconn.edu/10.1176
Kring AM, Barch DM (2014) The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur Neuropsychopharmacol 24(5):725–736. https://doi.org/10.1016/j.euroneuro.2013.06.007
doi: 10.1016/j.euroneuro.2013.06.007
pubmed: 24461724
pmcid: 4020953
Kurachi M, Shibata R, Murata M, Tanii Y (1995) Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration. Biol Psychiat 37:487–490
doi: 10.1016/0006-3223(94)00327-Y
pubmed: 7786966
Li M (2016) Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol 30:749–770. https://doi.org/10.1177/0269881116654697
doi: 10.1177/0269881116654697
pubmed: 27371498
pmcid: 4944179
Mai B, Sommer S, Hauber W (2012) Motivational states influence effort-based decision making in rats: the role of dopamine in the nucleus accumbens. Cogn Affect Behav Neurosci 12(1):74–84. https://doi.org/10.3758/s13415-011-0068-4
doi: 10.3758/s13415-011-0068-4
pubmed: 22012275
Mas S, Gassó P, Fernández de Bobadilla R, Arnaiz JA, Bernardo M, Lafuente A (2013) Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharmacol. 28(6):586–93. https://doi.org/10.1002/hup.2350
doi: 10.1002/hup.2350
pubmed: 24519692
McEvoy JP, Byerly M, Hamer RM et al (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311(19):1978–1987. https://doi.org/10.1001/jama.2014.4310
doi: 10.1001/jama.2014.4310
pubmed: 24846035
pmcid: 4101890
Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, Salamone JD (2009) The adenosine A2A MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a t-maze cost/benefit procedure. Psychopharmacology 204:103–112
doi: 10.1007/s00213-008-1441-z
pubmed: 19132351
pmcid: 2875244
Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, Sengoku R, Shimo Y, Hattori N (2019) Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci 396:78–83. https://doi.org/10.1016/j.jns.2018.11.005
doi: 10.1016/j.jns.2018.11.005
pubmed: 30423541
Nomoto M, Nagai M, Nishikawa N (2014) Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol 119:191–194. https://doi.org/10.1016/B978-0-12-801022-8.00009-X
doi: 10.1016/B978-0-12-801022-8.00009-X
pubmed: 25175967
Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M, Salamone JD (2010) Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 170(1):268–280. https://doi.org/10.1016/j.neuroscience.2010.05.068
doi: 10.1016/j.neuroscience.2010.05.068
pubmed: 20600675
Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y, Müller CE, López-Cruz L, Correa M, Salamone JD (2013) Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33(49):19120–19130. https://doi.org/10.1523/JNEUROSCI.2730-13.2013
doi: 10.1523/JNEUROSCI.2730-13.2013
pubmed: 24305809
pmcid: 3850037
Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone JD, Correa M (2012) Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology 62(5–6):2068–2077. https://doi.org/10.1016/j.neuropharm.2011.12.033
doi: 10.1016/j.neuropharm.2011.12.033
pubmed: 22261384
Pardo M, Paul NE, Collins-Praino LE, Salamone JD, Correa M (2020) The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making. Pharmacol Biochem Behav 198:173035. https://doi.org/10.1016/j.pbb.2020.173035
doi: 10.1016/j.pbb.2020.173035
pubmed: 32910928
Phan SV (2016) Medication adherence in patients with schizophrenia. Int J Psychiatry Med 51(2):211–219. https://doi.org/10.1177/0091217416636601
doi: 10.1177/0091217416636601
pubmed: 27079779
Randall PA, Pardo M, Nunes EJ, López Cruz L, Vemuri VK, Makriyannis A et al (2012) Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. Plos One 7(10):e47934. https://doi.org/10.1371/journal.pone.0047934
doi: 10.1371/journal.pone.0047934
pubmed: 23110135
pmcid: 3478264
Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, Shah P, Pandit S, Vemuri VK, Makriyannis A, Baqi Y, Müller CE, Correa M, Salamone JD (2014) The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. Plos One 9(6):e99320
doi: 10.1371/journal.pone.0099320
pubmed: 24937131
pmcid: 4061002
Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF (2015) Effort-based decision-making paradigms for clinical trials in schizophrenia: Part 1—Psychometric characteristics of 5 paradigms. Schizophr Bull 41(5):1045–1054. https://doi.org/10.1093/schbul/sbv089
Remington G, Kapur S (2010) Antipsychotic dosing: how much but also how often? Schiz Bull 36(5):900–903. https://doi.org/10.1093/schbul/sbq083
doi: 10.1093/schbul/sbq083
Rotolo RA, Dragacevic V, Kalaba P, Urban K, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA, Caria F, Schwartz R, Presby RE, Yang JH, Samels S, Correa M, Lubec G, Salamone JD (2019) The novel atypical dopamine uptake inhibitor (S)-CE-123 partially reverses the effort-related effects of the dopamine depleting agent tetrabenazine and increases progressive ratio responding. Front Pharm 10:682. https://doi.org/10.3389/fphar.2019.00682
doi: 10.3389/fphar.2019.00682
Rotolo RA, Kalaba P, Dragacevic V, Presby RE, Neri J, Robertson E, Yang JH, Correa M, Bakulev V, Volkova NN, Pifl C, Lubec G, Salamone JD (2020) Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding. Psychopharmacology 237(11):3459–3470. https://doi.org/10.1007/s00213-020-05625-6
doi: 10.1007/s00213-020-05625-6
pubmed: 32770257
pmcid: 7572767
Rotolo RA, Presby RE, Tracey O, Asar S, Yang J-H, Correa M, Murray F, Salamone JD (2021) The Novel Atypical Dopamine Transport Inhibitor CT-005404 Reverses the Effort-Related Motivational Effects of Tetrabenazine and Interleukin-1β and Increases Progressive Ratio Responding. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2020.108325
doi: 10.1016/j.neuropharm.2020.108325
pubmed: 32956676
Salamone JD, Correa M (2002) Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3–25
doi: 10.1016/S0166-4328(02)00282-6
pubmed: 12445713
Salamone JD, Correa M (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76:470–485
doi: 10.1016/j.neuron.2012.10.021
pubmed: 23141060
pmcid: 4450094
Salamone JD, Correa M (2022) Critical review of RDoC approaches to the study of motivation with animal models: effort valuation/willingness to work. Emerg Top Life Sci. https://doi.org/10.1042/ETLS20220008
doi: 10.1042/ETLS20220008
pubmed: 36218385
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology 104(4):515–521. https://doi.org/10.1007/BF02245659
doi: 10.1007/BF02245659
pubmed: 1780422
Salamone JD, Cousins MS, Bucher S (1994) Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res 65:221–229
doi: 10.1016/0166-4328(94)90108-2
pubmed: 7718155
Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus accumbens DA: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341–359
doi: 10.1016/S0149-7634(96)00017-6
pubmed: 9168269
Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM (2006) Nucleus accumbens dopamine and the forebrain circuitry involved in behavioral activation and effort-related decision making: implications for understanding anergia and psychomotor slowing in depression. Curr Psychiatry Rev 2:267–280
doi: 10.2174/157340006776875914
Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 191:461–482
doi: 10.1007/s00213-006-0668-9
pubmed: 17225164
Salamone JD, Correa M, Farrar AM, Nunes EJ, Collins LE (2010) Role of dopamine-adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation. Future Neurol 5:377–392
doi: 10.2217/fnl.10.19
Salamone JD, Yohn SE, Lopez-Cruz L, San Miguel N, Correa M (2016) Activational aspects of motivation: neural mechanisms and implications for psychopathology. Brain 139:1325–1347
doi: 10.1093/brain/aww050
pubmed: 27189581
pmcid: 5839596
Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (2018) The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation. Pharmacol Rev 70(4):747–762
doi: 10.1124/pr.117.015107
pubmed: 30209181
pmcid: 6169368
Salamone JD, Ecevitoglu A, Carratala-Ros C, Presby RE, Edelstein GA, Fleeher R, Rotolo RA, Meka N, Srinath S, Masthay JC, Correa M (2022) Complexities and paradoxes in understanding the role of dopamine in incentive motivation and instrumental action: Exertion of effort vs. anhedonia. Brain Res Bull 182:57–66. https://doi.org/10.1016/j.brainresbull.2022.01.019
doi: 10.1016/j.brainresbull.2022.01.019
pubmed: 35151797
Santerre JL, Nunes EJ, Kovner R et al (2012) The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol Biochem Behav 102(4):477–487. https://doi.org/10.1016/j.pbb.2012.06.009
doi: 10.1016/j.pbb.2012.06.009
pubmed: 22705392
Schweimer J, Saft S, Hauber W (2005) Involvement of catecholamine neurotransmission in the rat anterior cingulate in effort-related decision making. Behav Neurosci 119(6):1687–1692. https://doi.org/10.1037/0735-7044.119.6.1687
doi: 10.1037/0735-7044.119.6.1687
pubmed: 16420173
Sebel LE, Graves SM, Chan CS, Surmeier DJ (2017) Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits. Neuropsychopharmacology 42(4):963–973. https://doi.org/10.1038/npp.2016.173
doi: 10.1038/npp.2016.173
pubmed: 27577602
Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008) Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology 196(4):565–574. https://doi.org/10.1007/s00213-007-0988-4
doi: 10.1007/s00213-007-0988-4
pubmed: 18004546
Stahl SM (2002) The psychopharmacology of energy and fatigue. J Clin Psychiat 63:7–8
doi: 10.4088/JCP.v63n0102
Strauss GP, Waltz JA, Gold JM (2014) A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 40(Suppl 2):S107-166. https://doi.org/10.1093/schbul/sbt197
doi: 10.1093/schbul/sbt197
pubmed: 24375459
Strauss GP, Bartolomeo LA, Harvey PD (2021) Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr 7(1):16. https://doi.org/10.1038/s41537-021-00145-4
doi: 10.1038/s41537-021-00145-4
pubmed: 33637748
pmcid: 7910596
Tan T, Watts SW, Davis RP (2011) Drug Delivery: Enabling Technology for Drug Discovery and Development. Iprecio Micro Infusion Pump: Programmable, Refillable, and Implantable. Front Pharmacol 2:44. https://doi.org/10.3389/fphar.2011.00044
doi: 10.3389/fphar.2011.00044
pubmed: 21863140
pmcid: 3149148
Treadway MT, Salamone JD (2022) Vigor, Effort-Related Aspects of Motivation and Anhedonia. Curr Top Behav Neurosci 58:325–353. https://doi.org/10.1007/7854_2022_355
doi: 10.1007/7854_2022_355
pubmed: 35505057
Treadway MT, Zald DH (2011) Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 35:537–555
doi: 10.1016/j.neubiorev.2010.06.006
pubmed: 20603146
Treadway MT, Bossaller NA, Shelton RC, Zald DH (2012) Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 121(3):553–558
doi: 10.1037/a0028813
pubmed: 22775583
pmcid: 3730492
Treadway MT, Peterman JS, Zald DH, Park S (2015) Impaired effort allocation in patients with schizophrenia. Schizophr Res 161(2–3):382–385. https://doi.org/10.1016/j.schres.2014.11.024
doi: 10.1016/j.schres.2014.11.024
pubmed: 25487699
Trevitt J, Atherton A, Aberman J, Salamone JD (1998) Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology 137(1):61–66. https://doi.org/10.1007/s002130050593
doi: 10.1007/s002130050593
pubmed: 9631957
Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Müller CE, Salamone JD (2009) The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology 203:489–499
doi: 10.1007/s00213-008-1396-0
pubmed: 19048234
Xiao J, Mi W, Li L, Shi Y, Zhang H (2015) High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1161–7
pubmed: 26056450
pmcid: 4431492
Yang JH, Presby RE, Jarvie AA, Rotolo RA, Fitch RH, Correa M, Salamone JD (2020) Pharmacological studies of effort-related decision making using mouse touchscreen procedures: effects of dopamine antagonism do not resemble reinforcer devaluation by removal of food restriction. Psychopharmacology 237:33–43. https://doi.org/10.1007/s00213-019-05343-8
doi: 10.1007/s00213-019-05343-8
pubmed: 31392358
Yohn SE, Thompson C, Randall PA, Lee CA, Müller CE, Baqi Y, Correa M, Salamone JD (2015) The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology 232(7):1313–1323. https://doi.org/10.1007/s00213-014-3766-0
doi: 10.1007/s00213-014-3766-0
pubmed: 25323625